Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have formed a collaboration focused on developing medicines for pancreatic ductal adenocarcinoma (PDAC). The new collaboration combines MD Anderson's understanding of potential drivers of PDAC with Boehringer Ingelheim's experience in drug discovery and development.

The collaboration will focus on identifying and developing therapeutic concepts in novel target areas as well as identification of biomarkers that can accurately identify patients who would respond to potential new therapies.

Source: Boehringer Ingelheim